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Two phase II studies of S-1 monotherapy have shown promising response rates (RR) of 35–40% with good tolerability in patients
with untreated metastatic colorectal cancer. To investigate the usefulness of S-1 plus oxaliplatin (SOX) as an alternative to infusional
5-fluorouracil/leucovorin plus oxaliplatin, the recommended dose (RD) of SOX was determined, and its safety and preliminary
efficacy were evaluated in a phase I/II study. Oxaliplatin was administered at a dose of 100mgm
 2 (level 1) or 130mgm
 2 (level 2)
on day 1, and S-1 (80–120) was given twice daily for 2 weeks followed by a 1-week rest. This schedule was repeated every 3 weeks.
Level 2 was determined to be the RD. For the 28 patients who received the RD, the median treatment course was 6.5 cycles (2–14),
RR of 50% (1 CR and 13 PR: 95% CI 31–69%), with a median progression-free survival of 196 days. Survival rate (1 year) was 79%.
Peripheral neuropathy was observed in all patients but with no functional disorders. Major grade 3 or 4 adverse reactions at the RD
were neutropaenia (14%), thrombocytopaenia (28%), and diarrhoea (3%). SOX regimen is effective and easily manageable without
central vein access.
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Oral fluoropyrimidine derivatives have been developed to circumvent
the problems associated with continuous infusion of 5-fluorouracil
(5-FU). S-1 is an effective derivative that combines tegafur with two
modulators of 5-FU metabolism, 5-chloro-2,4-dihydroxypyridine
(CDHP), a reversible inhibitor of dihydropyrimidine dehydrogenase
(DPD), and potassium oxonate in a molar ratio of 1:0.4:1 (Kato
et al, 2001). Tegafur, an oral prodrug of 5-FU, is gradually converted
to 5-FU and rapidly metabolised by DPD in the liver. The maximum
concentration (Cmax) and area under the concentration–time curve
(AUC) of 5-FU in plasma during S-1 treatment have been found to be
higher than the steady-state concentration and AUC of 5-FU in
plasma during protracted intravenous infusion of 5-FU at a dose of
250mgm
 2day
 1 (Yamada et al, 2003).
Potassium oxonate is an orotate phosphoribosyl transferase
inhibitor that is distributed primarily to the gastrointestinal tract.
This component of S-1 decreases incorporation of 5-fluorouridine
triphosphate into RNA in the gastrointestinal mucosa and reduces
the incidence of diarrhoea. F-b-alanine (FBAL) is the main
metabolite of 5-FU. F-b-alanine and fluorocitrate are thought to
cause the neurotoxic and cardiotoxic effects of 5-FU by inhibiting the
tricarboxylic acid cycle (Okeda et al,1 9 9 0 ;R o b b e net al, 1993; Diasio
1998). The CDHP component of S-1 inhibits DPD, the rate-limiting
enzyme in the catabolic pathway of 5-FU. Consequently, the plasma
FBAL concentration after oral administration of S-1 is significantly
lower than that after continuous infusion of 5-FU (Yamada et al,
2003). Therefore, S-1 may decrease the incidence of neurotoxicity
and cardiotoxicity. The response rate of S-1 monotherapy has been
found to be 35–40% for patients with metastatic colorectal cancer
(Ohtsu et al, 2000; Shirao et al, 2004), with grade 3 or 4 neutropaenia
observed in 5–13%, thrombocytopaenia in 0–8%, diarrhoea in
2–3%, and grade 1 hand–foot syndrome (HFS) in 5%.
Oxaliplatin is a third-generation platinum compound with less
toxicity and improved convenience. The regimen of infusional
5-FU and leucovorin (LV) with oxaliplatin is the standard for first-
and second-line chemotherapy in patients with metastatic colo-
rectal cancer (de Gramont et al, 2000; Rothenberg et al, 2003;
Goldberg et al, 2004). However, infusional 5-FU with LV has the
disadvantages of increased inconvenience, cost, and morbidity
related to the use of a portable infusion pump and a central venous
catheter. Therefore, oral fluoropyrimidine monotherapy has been
commonly used in Japan.
The primary objectives of this phase I/II study were to determine
the maximum tolerated dose (MTD) of S-1 plus oxaliplatin (SOX). In
the phase II study, the toxicity and antitumour activity of SOX were
evaluated at the recommended dose (RD).
MATERIALS AND METHODS
Patient selection
Patients with histologically confirmed colorectal cancer who had
measurable metastatic disease were eligible for the study. Patients
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swith prior chemotherapy and radiotherapy for metastatic disease
were not permitted. Patients who had received adjuvant oral
fluorouracil-based therapy other than S-1 were eligible if they had
remained free of disease for at least 6 months after the completion
of such therapy. Other eligibility criteria included an age between
20 and 74 years; an Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1; adequate baseline bone marrow
function (white blood cell count more than the lower limit of
normal at each hospital and less than 12000ml
 1, neutrophil count
more than 2000ml
 1, and a platelet count more than 100000ml
 1),
hepatic function (serum total bilirubin (T.Bil) level 1.5 times the
upper limit of normal or less, and serum aspartate aminotransfer-
ase (AST) and alanine aminotransferase (ALT) 2.5 times the upper
limit of normal or less), and renal function (serum creatinine level
the upper limit of normal or less); and a life expectancy of at least
90 days. All patients gave written informed consent. Patients were
excluded if they had symptomatic brain metastasis, pre-existing
watery diarrhoea, or concomitant non-malignant disease, such as
cardiac, pulmonary, renal, or hepatic disease, or uncontrolled
infection. This study was approved by the institutional review
board of each centre. Before enrolment, all patients underwent a
physical examination (including documentation of measurable
disease), a complete blood cell count (CBC) with differential count,
serum chemical analysis, electrocardiography, and computed
tomographic (CT) scanning or magnetic resonance imaging (MRI).
Toxicity and response criteria
Toxicity was assessed according to the Common Terminology
Criteria for Adverse Events, Version 3.0 (CTCAE v3.0) (Therasse
et al, 2000). Neurotoxicity was assessed according to the following
specific neurotoxicity grading scale: grade 1, dysesthesia or
paresthesia that completely regressed within 6 days; grade 2,
dysesthesia or paresthesia persisting for 7 days or longer; and
grade 3, dysesthesia or paresthesia causing functional impairment.
During the study, all patients were evaluated weekly for signs and
symptoms of toxicity. Complete blood cell counts, including
differential count, liver function tests, measurement of urea
nitrogen, creatinine, and electrolyte levels, and urinalysis were
performed weekly. The response of measurable and assessable
disease sites was evaluated according to Response Evaluation
Criteria in Solid Tumors (RECIST) (Shimoyama, 1999). Tumour
dimensions were assessed by CT scanning or MRI every month to
confirm response, and after RECIST efficacy was confirmed, every
2 months subsequently.
Treatment plan
Oxaliplatin was administered as a 2-h infusion every 3 weeks. The
duration of the infusion could be extended to 6h in patients who
had pharyngolaryngeal dysesthesia during infusion. S-1 was
available in capsule forms containing 20 or 25mg of tegafur.
Patients received S-1 orally twice daily from the evening of day 1 to
the morning of day 15 at a dose of 40mg (BSAo1.25m
2), 50mg
(X1.25–o1.50m
2), or 60mg (X1.50m
2) followed by a 7-day rest
period in the 3-weekly schedule. All patients received premedica-
tion with a 5-hydroxytryptamine-3-receptor antagonist with or
without dexamethasone, given as a 30min drip infusion before
chemotherapy. Treatment was routinely given on an outpatient
basis. Subsequent treatment was withheld until the neutrophil and
platelet counts were greater than 1500 and 75000ml
 1, respectively,
AST or ALT less than 150IUl
 1, T.Bil less than 1.5 times the upper
limit of normal, creatinine less than the upper limit of normal, and
diarrhoea, stomatitis, and HFS had resolved to grade 0 or 1.
Treatment was repeated until the onset of disease progression or
severe toxicity. When the administration of oxaliplatin was
discontinued due to oxaliplatin-induced neuropathy, S-1 was also
discontinued.
Dose-escalation schedule
The dose of S-1 was fixed and oxaliplatin was examined at doses of
100mgm
 2 (level 1) and 130mgm
 2 (level 2). A minimum of
three patients were studied per dose level. Dose-limiting toxicity
(DLT) was defined as any of the following findings during cycle 1:
(i) a neutrophil count of less than 500ml
 1 for more than 4 days,
(ii) a platelet count of less than 50000ml
 1, (iii) diarrhoea of grade
3 or more that occurred despite adequate supportive therapy, (iv)
grade 3 or 4 non-haematologic toxicity, excluding nausea,
vomiting, anorexia, and electrolyte imbalance, or (v) a treatment
delay longer than 1 week due to drug-related toxicity in the phase I
portion. If DLT occurred in one of the first three patients assigned
to a given dose level, three additional patients were assigned to the
same dose level. The MTD was defined as the dose that induced
DLT during cycle 1 in 50% or more of the subjects. The RD was
defined as one dose level below the MTD. If the MTD was not
achieved, even at level 2, it was regarded as the RD.
The dose was modified for each patient based on haematologic
or non-haematologic toxicity. If DLT occurred, the dose of
oxaliplatin in the subsequent course was reduced to 75% of the
initial dose and that of S-1 was reduced by one dose level: from 80
to 50, 100 to 80, and 120 to 100. S-1 intake was interrupted mid-
cycle if there was a neutrophil count less than 1000ml
 1, a platelet
count less than 75000ml
 1, diarrhoea, stomatitis, or HFS occurred
at grade 1 or more, AST or ALT more than 150IUl
 1, T.Bil more
than 1.5 times the upper limit of normal, or creatinine more than
the upper limit of normal. The treatment in the subsequent cycle
could be resumed if these adverse events resolved within 3 weeks
after the last S-1 treatment. If peripheral neuropathy persisted
between courses, the next treatment cycle was started at 75% of the
previous dose of oxaliplatin. In a case with pharyngolaryngeal
dysesthesia, the duration of the oxaliplatin infusion was prolonged
from 2 to 6h. Recombinant granulocyte colony-stimulating factor
was subcutaneously injected if patients had grade 4 neutropaenia
or grade 3 febrile neutropaenia, but prophylactic use was not
allowed.
Statistical analysis
The sample size was calculated to be at least 28 patients on the
assumption of the null hypothesis of overall response rate of
p30% vs the alternative hypothesis of overall response rate of
460%, power 80%, and a 2.5% (one-sided). The efficacy was
analysed by the full analysis set. The primary end point was overall
response rate as determined by an External Review Board. The
95% CI for response rate was calculated. Twenty-eight evaluable
patients were required. Progression-free survival (PFS) and overall
survival were analysed by the Kaplan–Meier method. Safety was
analysed in all patients who received at least one dose of study
medications. Clinical cutoff date for the study analysis was 31 May
2007.
RESULTS
Patient characteristics
A total of 32 patients, 23 men and 9 women, were recruited into
this study between March 2005 and June 2006. The median age was
57 years. Four patients had received adjuvant oral fluorouracil-
based therapy. Out of 32 patients, 31 received at least one cycle of
the study treatment. The demographic data, sites of metastatic
tumour, and prior adjuvant therapies are summarised in Table 1.
Among the nine patients entered into the phase I study, six
patients were treated at the RD. Twenty-three patients entered into
the phase II study. However, one patient was excluded from the
analysis of efficacy due to symptoms of brain metastasis suspected
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sto have existed before enrolment. All 32 patients were evaluated for
toxicity and 28 patients for efficacy.
Dose-escalation findings
The first three patients were enrolled at dose level 1 (oxaliplatin
100mgm
 2, S-1 80–120mgday
 1). No DLTs were observed, and
six patients were enrolled at dose level 2 (oxaliplatin 130mgm
 2,
S-1 80–120mgday
 1). At level 1, one patient had grade 3
thrombocytopaenia. At level 2, one patient had grade 3 neutro-
paenia and one patient had grade 4 thrombocytopaenia. The RD
was determined to be 130mgm
 2 of oxaliplatin in combination
with the Japanese standard daily dose of S-1.
Safety assessment
After identification of tolerability at level 2 (130mgm
 2)o f
oxaliplatin, 29 other patients received the RD at 130mgm
 2,
including the phase I part patients, to further evaluate the
tolerability and toxicity of the study regimen. The median number
of administered cycles was 6.5 (range: 2–14), and the total number
of cycles for the 29 patients was 180. Oxaliplatin could be
administered at the RD without dose reduction in 57% of 28
patients. At the RD, grade 3 neutropaenia was observed in four
patients (14%), and grade 3 and 4 thrombocytopaenia in seven
patients (24%) and one patient (3%), respectively. The median
relative dose intensity was 82.8% for oxaliplatin and 74.6% for S-1
at level 2. The causes of treatment discontinuation at the RD were
PD in 13 patients (36%), delayed recovery from toxicity such as
neutropaenia, thrombocytopaenia, and slight hyperbilirubinaemia
in 8 patients, discretion of the investigator in 2 patients, allergic
reaction in 1 patient, and symptomatic deterioration in 1 patient.
The treatment was discontinued due to prolonged thrombocyto-
paenia in eight patients after a median of seven cycles (range:
3–8). No treatment-related death was observed.
Sensory neuropathy occurred in all patients. However, no
functional impairment was observed in this study. The most
common non-haematologic toxicities were anorexia, nausea, and
diarrhoea. One patient had grade 3 diarrhoea at the RD. Another
mild adverse event related to treatment was injection site reactions
(45%). One patient had severe allergic reactions such as skin rash
and fever, which are typical platinum-related reactions during the
sixth cycle (Table 2).
Response to therapy
The objective tumour response was determined by the External
Review Board. One of the 28 patients given the RD at level 2 had
CR and 13 patients had PR, yielding a response rate of 50% (95%
CI: 30.6–69.4%). In the 28 patients studied, the median PFS was
Table 1 Patients characteristics
Level 1, n¼3 Level 2, n¼29
L-OHP (100mgm
 2) L-OHP (130mgm
 2)
Characteristic No. of patients (%) No. of patients (%)
Age (years)
Median 57 57
Range 47–60 34–71
Sex
Male 3 (100) 20 (69)
Female 0 9 (31)
ECOG performance status
0 3 (100) 26 (90)
1 0 3 (10)
Primary tumour
Colon 2 (67) 18 (62)
Rectum 1 (33) 11 (38)
Metastatic site
Liver only 1 (33) 10 (35)
Lung 0 3 (10)
Liver and other lesions 1 (33) 10 (35)
Others 1 (33) 6 (21)
No. of metastatic sites
1 1 (33) 15 (52)
X2 2 (67) 14 (48)
Previous treatment
Resection 2 (67) 25 (86)
Adjuvant 5-FU 0 4 (14)
ECOG¼Eastern Cooperative Oncology Group; L-OHP¼oxaliplatin.
Table 2 Toxicity
Level 1, L-OHP (100mgm
 2), n¼3 Level 2, L-OHP (130mgm
 2), n¼29
All (%) G3 (%) G4 (%) All (%) G3 (%) G4 (%)
Non-haematologic
Nausea 1 (33) 0 0 21 (72) 0 0
Vomiting 0 0 0 7 (24) 0 0
Diarrhoea 1 (33) 0 0 17 (59) 1 (3) 0
Fatigue 1 (33) 0 0 25 (86) 0 0
Anorexia 2 (67) 0 0 26 (90) 0 0
Rush 3 (100) 0 0 13 (45) 0 0
Pigmentation disorder 1 (33) 0 0 22 (76) 0 0
Hand–foot syndrome 0 0 0 0 0 0
Peripheral neuropathy 3 (100) 0 0 29 (100) 0 0
Allergic reaction 0 0 0 0 1 (3) 0
Haematologic
Neutropaenia 2 (67) 0 0 18 (62) 4 (14) 0
Leukopaenia 2 (67) 0 0 20 (69) 0 0
Thrombocytopaenia 3 (100) 1 (33) 0 27 (93) 7 (24) 1 (3)
Anaemia 1 (33) 0 0 18 (62) 1 (3) 0
L-OHP¼oxaliplatin.
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s196 days (95% CI: 167–303). The median overall survival time was
not reached when 1 year passed since the last patient enrolment,
namely 18 patients were alive and 10 patients were dead, and the
1-year survival rate was 78.6% by the Kaplan–Meier method
(Table 3) (Figures 1 and 2).
DISCUSSION
Our results suggest that SOX regimen is safe and effective as a
first-line treatment for metastatic colorectal cancer. The RD was
determined to be 130mgm
 2 of oxaliplatin on day 1 with 40–
60mg of S-1 twice daily from the evening of day 1 to the morning
of day 15, followed by a 7-day rest period in a 3-weekly schedule.
This result indicates that both oxaliplatin and S-1 could be
administered at doses similar to those recommended for mono-
therapy for each drug. SOX regimen has demonstrated promising
efficacy with a response rate of 50%, median PFS of 196 days, and a
1-year survival rate of 78.6%. Efficacy of this combination is
superior to that reported for monotherapy by each drug (Diaz-
Rubio et al, 1998; Ohtsu et al, 2000; Shirao et al, 2004; Boku et al,
2007). No DLTs were observed during the first cycle at levels 1 and
2. At the RD (level 2), the toxicity profile was acceptable. The
frequent non-haematologic toxicities were anorexia, nausea, and
diarrhoea. Most cases of gastrointestinal toxicity were grade 1 or 2,
and good oral intake was maintained. There was no grade 3
neurotoxicity observed. Although the incidence of grade 3 or 4
thrombocytopaenia seems to be higher with SOX compared with
the reported result of FOLFOX4 (Diaz-Rubio et al, 1998; Shirao
et al, 2004), it was well managed by adequate dose modification of
oxaliplatin and S-1 in subsequent cycles (Goldberg et al, 2004).
Since the severity of thrombocytopaenia is dependent on the dose
of oxaliplatin, FOLFOX7 with oxaliplatin at a dose of 130mgm
 2
caused 9% of grade 3 thrombocytopaenia (Maindrault-Gœbel et al,
2001; Tournigand et al, 2006).
The median time to first dose reduction was five cycles (range:
2–7) due to any reason in 16 of the 28 patients at the RD, and 4.5
cycles (range: 3–5) due to grade 3 or 4 thrombocytopaenia in 6 of
the 28 patients. Therapy was delayed in 22 of the 28 patients and 40
of 209 cycles, commonly due to neutropaenia, thrombocytopaenia,
and sensory peripheral neuropathy. SOX requires only one clinic
visit per 3-week cycle for a 2-h infusion of oxaliplatin. This
convenience constitutes a marked advantage over regimens
combining infused 5-FU/LV by ambulatory pump and oxaliplatin
in terms of the impact on the daily lives of patients. In addition,
very busy hospitals may have logistic issues providing pumps to all
patients; therefore, oral S-1 offers an advantage over infusional
5-FU in respects of convenience and practicability.
The combination regimens of other oral fluoropyrimidine,
capecitabine, and oxaliplatin have been reported in other phase
II and III studies. Cassidy et al (2004) reported the results of a
phase II study of oxaliplatin plus capecitabine (XELOX) as a first-
line therapy in patients with colorectal cancer (Dı ´az-Rubio et al,
2002). Oxaliplatin (130mgm
 2) was administered on day 1 and
capecitabine (2000mgm
 2day
 1) for 14 days with a 1-week rest,
every 3 weeks. The response rate, median TTP, and MST were 55%,
7.7 months, and 19.5 months, respectively. Grade 3 or 4
neutropaenia according to NCI-CTC developed in 7% of patients
by XELOX, and grade 3 or 4 diarrhoea developed in 16%.
The efficacy and safety of XELOX were also compared with that
of 5-FU/LV plus oxaliplatin regimens (FUOX) in several phase III
studies. The efficacy of XELOX was statistically not inferior to that
of the FUOX regimen: median TTP 8.9 vs 9.5 months (P¼0.153),
and MST 18.1 vs 20.8 months (P¼0.145) (Dı ´az-Rubio et al, 2007).
Grade 3 or 4 diarrhoea was observed in 14% with both XELOX and
FUOX regimens, respectively, and grade 3 or 4 HFS in 2% with
XELOX. The efficacy of XELOX was also statistically not inferior to
that of FOLFOX4: median TTP 8.0 vs 8.5 months, and MST 18.8 vs
17.7 months (Cassidy et al, 2007). Grade 3 or 4 diarrhoea was
observed in 20% with XELOX and 11% with FOLFOX4, and grade 3
HFS in 6% with XELOX and 1% with FOLFOX4. Other schedules of
oxaliplatin and capecitabine (CAPOX: 70mgm
 2 oxaliplatin on
days 1 and 8 and 2000mgm
 2day
 1 capecitabine for 14 days with
a 1-week rest) were compared with FUFOX. CAPOX was slightly
inferior to FUFOX in TTP: median TTP 7.1 vs 8.0 months
(P¼0.117), and MST 16.8 vs 18.8 months (P¼0.26) (Porschen
et al, 2007). Both regimens were generally well tolerated, although
grade 2 or 3 HFS occurred more often with CAPOX (10 vs 4%)
(P¼0.028). In summary, the results of these phase III studies show
that the efficacy of XELOX or CAPOX was not inferior to or was
slightly inferior to that of infusional 5-FU/LV plus oxaliplatin
regimens. Although HFS is more commonly observed in capeci-
tabine-combined regimens, capecitabine is expected to replace
infusional 5-FU/LV.
Our limited experience of SOX regimen suggests that tri-weekly
treatment with oxaliplatin and S-1 may be comparable to that of
XELOX or CAPOX. The response rate of SOX was 50%, suggesting
that it is worth while comparing the efficacy of SOX with that of
XELOX in the phase III study. Grade 3 or 4 thrombocytopaenia
was observed in 28% of patients, and this incidence seems to be
higher than that reported by FOLFOX4 (de Gramont et al, 2000).
Table 3 Response rate
No. of
patients CR PR SD PD
Response
rate (%)
Level 1
L-OHP (100mgm
 2) 3 0 2 1 0 67 (CI: 9.4–99.2)
Level 2
L-OHP (130mgm
 2) 28 1 13 9 5 50 (CI: 30.6–69.4)
CI¼confidence interval; CR¼complete response; L-OHP¼oxaliplatin; PD¼
progressive disease; PR¼partial response; SD¼stable disease.
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sGrade 3 or 4 thrombocytopaenia with oxaliplatin monotherapy was
reported in 12% of patients (Boku et al, 2007), and that with S-1
monotherapy in 0–8% of patients in previous phase II studies
(Ohtsu et al, 2000; Shirao et al, 2004). The most commonly
observed grade 3 or 4 toxicity after SOX therapy was cumulative
prolonged thrombocytopaenia in this phase I/II trial, which is a
well-known toxicity of oxaliplatin. The protocol therapy was
discontinued due to prolonged thrombocytopaenia in seven
patients after a median of seven cycles (range: 3–8). In cases
where sudden and severe thrombocytopaenia is observed, type II
allergic reaction to oxaliplatin should be considered and definitive
withdrawal is strongly suggested (Maindrault-Gœbel et al, 2001). A
phase I study of XELOX with 130mgm
 2 of oxaliplatin tri-weekly
has also shown a relatively higher incidence of grade 3
thrombocytopaenia in 22% (Dı ´az-Rubio et al, 2002), but only 4%
during phase II with weekly assessment of CBC (Cassidy et al,
2004). Thrombocytopaenia of SOX should be evaluated in the
future phase II or III studies with a larger number of patients.
In conclusion, SOX holds promise of being a safe and effective
treatment for metastatic colorectal cancer. Further evaluation is
expected to examine whether SOX can be a substitute for FOLFOX.
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